CF PHARMTECH

CF PharmTech opened at HK$16.80 and briefly hit a morning high of HK$16.92 before steadily declining, with an afternoon acceleration to an intraday low of HK$15.88, closing at that level, down 5.08% for the session. The day's total turnover was approximately HK$50.14 million, with a turnover rate of 0.95%. The selloff was primarily driven by lingering market digestion of the company's recent discounted H-share placement, where it placed about 21.75 million new shares at HK$13.82 each (a ~17.4% discount to the previous close) to raise approximately HK$301 million for innovative drug R&D, triggering investor concerns that had already sent the stock down ~15% since the announcement. While Q1 2025 results showed a slight 3.88% YoY revenue decline to HK$145.6 million, net profit surged 105.84% YoY to HK$13.72 million, driving the net profit margin to 9.43%, this improvement in earnings quality failed to offset the downward pressure. The stock remains 67.46% below its 52-week high of HK$48.80 and is trading below both the 20-day MA (HK$16.75) and 60-day MA (HK$18.01), indicating weak technical positioning. Though the company's recent move to adjust the board lot size may support future liquidity.

CF PharmTech gapped down and fell further in the afternoon session, closing 5% lower at HK$16.64. The decline was mainly attributed to the dilutive effect of the company's discounted H-share placement of ~21.75 million new shares at HK$13.82 each, announced earlier. The stock hit an intraday low of HK$16.64, ending below its 60-day moving average of HK$18.13 and approaching the 52-week low of HK$14.82, with a YTD drop of 51%. While Q1 net profit surged 105.84% YoY to HK$13.73 million and net margin improved from 4.4% to 9.4%, revenue edged down 3.9% to HK$145.6 million, and the elevated PE of 2614.8x remains a concern. Recent board changes and potential southbound inflows could offer some support, though.

2652.HK opened low and rallied in the morning session, closing up 5.22% at HKD 16.95, driven mainly by improved liquidity sentiment following the completion of a 21.777 million new H-share placement at HKD 13.82 each on May 13, raising approximately HKD 300 million, alongside positive earnings momentum. Q1 2025 net profit surged 105.84% YoY to HKD 13.72 million, operating income rose 216.71% YoY, and net profit margin improved to 9.43%, though revenue edged down 3.88% YoY. The stock remains 65.27% below its 52-week high of HKD 48.8 and below the MA60 (HKD 18.182), but has reclaimed the MA20 (HKD 16.587) and is 14.37% above the 52-week low of HKD 14.82. However, the YTD decline still stands at 50.09%, and the PE ratio of 2,663x highlights persistent valuation concerns.

CF PharmTech ended the afternoon session down 4.33% at HK$16.60, hitting an intraday low of HK$16.51, a new 52-week trough. The price decline was driven by the recent placement of 21.75 million new H-shares at HK$13.82 each, diluting existing holders, coupled with a 3.88% YoY drop in Q1 revenue to HK$145.6 million. Despite Q1 net profit surging 105.84% YoY to HK$13.72 million and net profit margin expanding from 4.40% to 9.43%, the stock remained under pressure from the capital raise. Current price is 65.98% below the 52-week high of HK$48.80, with a YTD loss of 51.12%, barely above the 20-day MA (HK$16.58) but well below the 60-day MA (HK$18.25), indicating a weak medium-term trend. However, operating income jumped 216.71% YoY to HK$9.21 million, hinting at improving operational efficiency.

CF PharmTech opened higher and rallied through the morning session, climbing from HK$17.05 to HK$18.08, closing up 5.06%, driven by the recent completion of an H-share placement of 21.75 million new shares raising approximately HK$300 million at a price of HK$13.82, a discount of about 19.7% to the previous close. Financially, Q1 2025 net profit surged 105.84% YoY to HK$13.72 million, operating profit turned positive to HK$9.21 million, and net margin expanded from 4.4% to 9.4%, though revenue edged down 3.88% YoY to HK$145.6 million. The current price of HK$18.08 remains 63% below the 52-week high of HK$48.80, with a YTD decline of 46.76%, yet it has risen 22% from the 52-week low of HK$14.82 and sits above the 20-day MA of HK$16.65, albeit still below the 60-day MA of HK$18.34.